Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Total Non-Current Liabilities data on file, last reported at $46.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 19.87% year-over-year to $46.3 million; the trailing twelve-month figure through Mar 2026 stood at $46.3 million (down 19.87% YoY), and the FY2025 full-year result was $52.2 million, down 17.62% from the prior year.
• Total Non-Current Liabilities slipped to $46.3 million in Q1 2026, from $52.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $70.8 million in Q4 2023 to a low of $42.5 million in Q1 2022.
• A 5-year average of $56.0 million and a median of $56.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Peak annual rise in Total Non-Current Liabilities reached 41.0% in 2022, while the deepest fall reached 55.93% in 2022.
• Tracing RCKT's Total Non-Current Liabilities over 5 years: stood at $59.5 million in 2022, then grew by 18.99% to $70.8 million in 2023, then fell by 10.6% to $63.3 million in 2024, then fell by 17.62% to $52.2 million in 2025, then slipped by 11.24% to $46.3 million in 2026.
• Business Quant data shows RCKT's Total Non-Current Liabilities at $46.3 million in Q1 2026, $52.2 million in Q4 2025, and $53.3 million in Q3 2025.